John W McEvoy1, Seth S Martin2, Zeina A Dardari2, Michael D Miedema2, Veit Sandfort2, Joseph Yeboah2, Matthew J Budoff2, David C Goff2, Bruce M Psaty2, Wendy S Post2, Khurram Nasir2, Roger S Blumenthal2, Michael J Blaha2. 1. From Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University School of Medicine, Baltimore, MD (J.W.M., S.S.M., Z.A.D., W.S.P., K.N., R.S.B., M.J.Blaha); Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, MN (M.D.M.); Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD (V.S.); Heart and Vascular Center of Excellence, Wake Forest Baptist Health, Winston-Salem, NC (J.Y.); Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA (M.J.Budoff); Department of Epidemiology, Colorado School of Public Health, Aurora (D.C.G.); Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington, Seattle (B.M.P.); and Center for Healthcare Advancement and Outcomes and Miami Cardiac and Vascular Institute, Baptist Health South Florida (K.N.). jmcevoy1@jhmi.edu. 2. From Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University School of Medicine, Baltimore, MD (J.W.M., S.S.M., Z.A.D., W.S.P., K.N., R.S.B., M.J.Blaha); Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, MN (M.D.M.); Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD (V.S.); Heart and Vascular Center of Excellence, Wake Forest Baptist Health, Winston-Salem, NC (J.Y.); Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA (M.J.Budoff); Department of Epidemiology, Colorado School of Public Health, Aurora (D.C.G.); Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington, Seattle (B.M.P.); and Center for Healthcare Advancement and Outcomes and Miami Cardiac and Vascular Institute, Baptist Health South Florida (K.N.).
Abstract
BACKGROUND: The use of atherosclerotic cardiovascular disease (ASCVD) risk to personalize systolic blood pressure (SBP) treatment goals is a topic of increasing interest. Therefore, we studied whether coronary artery calcium (CAC) can further guide the allocation of anti-hypertensive treatment intensity. METHODS: We included 3733 participants from the Multi-Ethnic Study of Atherosclerosis (MESA) with SBP between 120 and 179 mm Hg. Within subgroups categorized by both SBP (120-139 mm Hg, 140-159 mm Hg, and 160-179 mm Hg) and estimated 10-year ASCVD risk (using the American College of Cardiology/American Heart Assocation pooled-cohort equations), we compared multivariable-adjusted hazard ratios for the composite outcome of incident ASCVD or heart failure after further stratifying by CAC (0, 1-100, or >100). We estimated 10-year number-needed-to-treat for an intensive SBP goal of 120 mm Hg by applying the treatment benefit recorded in meta-analyses to event rates within CAC strata. RESULTS: The mean age was 65 years, and 642 composite events took place over a median of 10.2 years. In persons with SBP <160 mm Hg, CAC stratified risk for events. For example, among those with an ASCVD risk of <15% and who had an SBP of either 120 to 139 mm Hg or 140 to 159 mm Hg, respectively, we found increasing hazard ratios for events with CAC 1 to 100 (1.7 [95% confidence interval, 1.0-2.6] or 2.0 [1.1-3.8]) and CAC >100 (3.0 [1.8-5.0] or 5.7 [2.9-11.0]), all relative to CAC=0. There appeared to be no statistical association between CAC and events when SBP was 160 to 179 mm Hg, irrespective of ASCVD risk level. Estimated 10-year number-needed-to-treat for a SBP goal of 120mmHg varied substantially according to CAC levels when predicted ASCVD risk <15% and SBP <160mmHg (eg, 10-year number-needed-to-treat of 99 for CAC=0 and 24 for CAC>100, when SBP 120-139mm Hg). However, few participants with ASCVD risk <5% had elevated CAC. Furthermore, 10-year number-needed-to-treat estimates were consistently low and varied less among CAC strata when SBP was 160 to 179 mm Hg or when ASCVD risk was ≥15% at any SBP level. CONCLUSIONS: Combined CAC imaging and assessment of global ASCVD risk has the potential to guide personalized SBP goals (eg, choosing a traditional goal of 140 or a more intensive goal of 120 mm Hg), particularly among adults with an estimated ASCVD risk of 5% to 15% and prehypertension or mild hypertension.
BACKGROUND: The use of atherosclerotic cardiovascular disease (ASCVD) risk to personalize systolic blood pressure (SBP) treatment goals is a topic of increasing interest. Therefore, we studied whether coronary artery calcium (CAC) can further guide the allocation of anti-hypertensive treatment intensity. METHODS: We included 3733 participants from the Multi-Ethnic Study of Atherosclerosis (MESA) with SBP between 120 and 179 mm Hg. Within subgroups categorized by both SBP (120-139 mm Hg, 140-159 mm Hg, and 160-179 mm Hg) and estimated 10-year ASCVD risk (using the American College of Cardiology/American Heart Assocation pooled-cohort equations), we compared multivariable-adjusted hazard ratios for the composite outcome of incident ASCVD or heart failure after further stratifying by CAC (0, 1-100, or >100). We estimated 10-year number-needed-to-treat for an intensive SBP goal of 120 mm Hg by applying the treatment benefit recorded in meta-analyses to event rates within CAC strata. RESULTS: The mean age was 65 years, and 642 composite events took place over a median of 10.2 years. In persons with SBP <160 mm Hg, CAC stratified risk for events. For example, among those with an ASCVD risk of <15% and who had an SBP of either 120 to 139 mm Hg or 140 to 159 mm Hg, respectively, we found increasing hazard ratios for events with CAC 1 to 100 (1.7 [95% confidence interval, 1.0-2.6] or 2.0 [1.1-3.8]) and CAC >100 (3.0 [1.8-5.0] or 5.7 [2.9-11.0]), all relative to CAC=0. There appeared to be no statistical association between CAC and events when SBP was 160 to 179 mm Hg, irrespective of ASCVD risk level. Estimated 10-year number-needed-to-treat for a SBP goal of 120mmHg varied substantially according to CAC levels when predicted ASCVD risk <15% and SBP <160mmHg (eg, 10-year number-needed-to-treat of 99 for CAC=0 and 24 for CAC>100, when SBP 120-139mm Hg). However, few participants with ASCVD risk <5% had elevated CAC. Furthermore, 10-year number-needed-to-treat estimates were consistently low and varied less among CAC strata when SBP was 160 to 179 mm Hg or when ASCVD risk was ≥15% at any SBP level. CONCLUSIONS: Combined CAC imaging and assessment of global ASCVD risk has the potential to guide personalized SBP goals (eg, choosing a traditional goal of 140 or a more intensive goal of 120 mm Hg), particularly among adults with an estimated ASCVD risk of 5% to 15% and prehypertension or mild hypertension.
Authors: Rod Jackson; Carlene M M Lawes; Derrick A Bennett; Richard J Milne; Anthony Rodgers Journal: Lancet Date: 2005 Jan 29-Feb 4 Impact factor: 79.321
Authors: J Jeffrey Carr; Jennifer Clark Nelson; Nathan D Wong; Michael McNitt-Gray; Yadon Arad; David R Jacobs; Stephan Sidney; Diane E Bild; O Dale Williams; Robert C Detrano Journal: Radiology Date: 2005-01 Impact factor: 11.105
Authors: Andrew P DeFilippis; Rebekah Young; Christopher J Carrubba; John W McEvoy; Matthew J Budoff; Roger S Blumenthal; Richard A Kronmal; Robyn L McClelland; Khurram Nasir; Michael J Blaha Journal: Ann Intern Med Date: 2015-02-17 Impact factor: 25.391
Authors: Valentina Valenti; Bríain Ó Hartaigh; Ran Heo; Joshua Schulman-Marcus; Iksung Cho; Dan K Kalra; Quynh A Truong; Ashley E Giambrone; Heidi Gransar; Tracy Q Callister; Leslee J Shaw; Fay Y Lin; Hyuk-Jae Chang; Sebastiano Sciarretta; James K Min Journal: Int J Cardiol Date: 2015-03-05 Impact factor: 4.164
Authors: Michael D Miedema; Daniel A Duprez; Jeffrey R Misialek; Michael J Blaha; Khurram Nasir; Michael G Silverman; Ron Blankstein; Matthew J Budoff; Philip Greenland; Aaron R Folsom Journal: Circ Cardiovasc Qual Outcomes Date: 2014-05-06
Authors: Ilana B Richman; Michael Fairley; Mads Emil Jørgensen; Alejandro Schuler; Douglas K Owens; Jeremy D Goldhaber-Fiebert Journal: JAMA Cardiol Date: 2016-11-01 Impact factor: 14.676
Authors: Adam P Bress; Rikki M Tanner; Rachel Hess; Lisandro D Colantonio; Daichi Shimbo; Paul Muntner Journal: J Am Coll Cardiol Date: 2015-11-09 Impact factor: 24.094
Authors: Xinfang Xie; Emily Atkins; Jicheng Lv; Alexander Bennett; Bruce Neal; Toshiharu Ninomiya; Mark Woodward; Stephen MacMahon; Fiona Turnbull; Graham S Hillis; John Chalmers; Jonathan Mant; Abdul Salam; Kazem Rahimi; Vlado Perkovic; Anthony Rodgers Journal: Lancet Date: 2015-11-07 Impact factor: 79.321
Authors: Mahmoud Al Rifai; Miguel Cainzos-Achirica; Sina Kianoush; Mohammadhassan Mirbolouk; Allison Peng; Josep Comin-Colet; Michael J Blaha Journal: Curr Treat Options Cardiovasc Med Date: 2018-09-26
Authors: Amer I Aladin; Mahmoud Al Rifai; Shereen H Rasool; Zeina Dardari; Joseph Yeboah; Khurram Nasir; Matthew J Budoff; Bruce M Psaty; Roger S Blumenthal; Michael J Blaha; John W McEvoy Journal: Am J Cardiol Date: 2017-10-24 Impact factor: 2.778
Authors: Mahmoud Al Rifai; Miguel Cainzos-Achirica; Alka M Kanaya; Namratha R Kandula; Zeina Dardardi; Parag H Joshi; Jaideep Patel; Matthew Budoff; Joseph Yeboah; Eliseo Guallar; Roger S Blumenthal; Michael J Blaha Journal: Atherosclerosis Date: 2018-09-15 Impact factor: 5.162
Authors: Olusola A Orimoloye; Sandeep Banga; Zeina A Dardari; S M Iftekhar Uddin; Matthew J Budoff; Daniel S Berman; Alan Rozanski; Leslee J Shaw; John A Rumberger; Khurram Nasir; Michael D Miedema; Roger S Blumenthal; Michael J Blaha; Mohammadhassan Mirbolouk Journal: Coron Artery Dis Date: 2019-12 Impact factor: 1.439
Authors: Ambarish Pandey; Kershaw V Patel; Wanpen Vongpatanasin; Colby Ayers; Jarett D Berry; Robert J Mentz; Michael J Blaha; John W McEvoy; Paul Muntner; Muthiah Vaduganathan; Adolfo Correa; Javed Butler; Daichi Shimbo; Vijay Nambi; Christopher deFilippi; Stephen L Seliger; Christie M Ballantyne; Elizabeth Selvin; James A de Lemos; Parag H Joshi Journal: Circulation Date: 2019-11-11 Impact factor: 29.690
Authors: Faisal Rahman; Mahmoud Al Rifai; Michael J Blaha; Khurram Nasir; Matthew J Budoff; Bruce M Psaty; Wendy S Post; Roger S Blumenthal; John W McEvoy Journal: Am J Cardiol Date: 2017-08-08 Impact factor: 2.778